Investigation Report on China’s Pancreatic Kininogenase Market, 2018-2022

admin — Wed, 02 Jan 2019 02:40:08 +0000

Description
The incidence of and the death rate from cardiovascular and cerebrovascular diseases are increasing in China with the development of economy, the change of lifestyle and the aging of the population. It is estimated that nearly 300 million people in China are suffering from cardiovascular and cerebrovascular diseases. The number of patients with stroke, coronary heart disease, heart failure, pulmonary heart disease, rheumatic heart disease, congenital heart disease and hypertension amounts to 13 million, 11 million, 4.5 million, 5 million, 2.5 million, 2 million and 270 million respectively. With a higher death rate than tumors and other diseases, cardiovascular diseases account for more than 40% disease deaths in China. In particular, rural areas have seen higher death rate from cardiovascular diseases than urban areas in recent years. And the costs of hospitalization resulting from cardiovascular and cerebrovascular diseases are also increasing sharply.
Pancreatic Kininogenase can be used to treat cardiovascular and cerebrovascular diseases such as primary hypertension, arteriosclerosis, coronary atherosclerotic heart disease, cerebral arteriosclerosis, cerebral thrombosis, retinal vascular disorder and peripheral vascular disease. Recent studies have found that Pancreatic Kininogenase can also be used to prevent diabetic microangiopathy and early diabetic nephropathy by reducing the discharge of urinary albumin. In addition, Pancreatic Kininogenase can increase the activity and production of sperms, and thus has certain curative effect on male infertility, according to domestic clinical data.
In 1999, Changzhou Qianhong Bio-pharma Co., Ltd.’s Pancreatic Kininogenase was first launched in China, followed by the counterparts of Chengdu Tongde Pharmaceutical Co., Ltd., Henan Livu Pharmacy Co., Ltd., Shanghai Livzon Pharmaceutical Co., Ltd., etc. At present, there are seven Pancreatic Kininogenase manufacturers in China. Changzhou Qianhong Bio-pharma Co., Ltd.’s Pancreatic Kininogenase (trade name: Yikai) takes up about 90% market share by sales value.
It is expected that as the incidence of cardiovascular and cerebrovascular diseases continues to increase, China’s Pancreatic Kininogenase market will still have some growth potential in the next few years.

Topics Covered:
– Situation of cardiovascular and cerebrovascular diseases in China
– Status of China’s Pancreatic Kininogenase market
– Competition on China’s Pancreatic Kininogenase market
– Factors influencing the development of China’s Pancreatic Kininogenase market
– Prospect of China’s Pancreatic Kininogenase market

The post Investigation Report on China’s Pancreatic Kininogenase Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Entecavir Market, 2018-2022

admin — Wed, 02 Jan 2019 02:36:16 +0000

Description
In China, more than 100 billion people are chronically infected with hepatitis B virus (HBV), of which 20 million to 30 million have chronic hepatitis B. It is estimated that every year, more than 500,000 people in China die of the liver damage or liver cancer caused by chronic hepatitis B, which leads to losses of over CNY 100 billion.
Developed by Bristol-Myers Squibb, Entecavir is a nucleoside analogue taken by mouth. In Mar. 2005, Entecavir was approved by the FDA. Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir was launched in China at the beginning of 2006 after being approved by the China Food and Drug Administration (CFDA) at the end of 2005. Later, Chinese pharmaceutical companies launched generic Entecavir successively, which drove the growth of the market.
According to CRI’s market research, the annual sales value of Entecavir increased from over CNY 30 million in 2006 to CNY 2.03 billion in 2016, and decreased slightly in 2017. Sino-American Shanghai Squibb Pharmaceuticals Ltd.’s Entecavir still dominates the market. Its market share by sales value reached about 40% in 2017 but is shrinking as impacted by China-made generic drugs.
Entecavir has better and faster antiviral effect and see less side effects and drug resistance than traditional nucleoside analogs. Having a high genetic barrier to resistance, it is a powerful and long-acting HBV inhibitor for early monotherapy. As the demand for new anti-HBV drugs is far from being met, China’s Entecavir market is promising with rising sales value in the coming years.

Topics Covered:
– Development environment of China’s Entecavir market
– Size of China’s Entecavir market
– Competitive landscape of China’s Entecavir market
– Prices of Entecavir in China
– Major factors influencing the development of China’s Entecavir market
– Prospect of China’s Entecavir market

The post Investigation Report on China’s Entecavir Market, 2018-2022 first appeared on CRI Report.

2019/1/1 – CRI Report

Investigation Report on China’s Pancreatic Kininogenase Market, 2018-2022

Investigation Report on China’s Entecavir Market, 2018-2022